Selected research
Market Structure
Global Niraparib Preparations Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Niraparib Preparations market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Niraparib Preparations is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Niraparib Preparations is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Niraparib Preparations is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Niraparib Preparations is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Niraparib Preparations include Zai Lab, Takeda Pharmaceutical, Janssen Biotech and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Niraparib Preparations market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Niraparib Preparations and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Niraparib Preparations sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Niraparib Preparations market size, projected growth trends, production technologies, key applications, and end-use industries.
Niraparib Preparations Segment by Company
Zai Lab
Takeda Pharmaceutical
Janssen Biotech
GSK
Niraparib Preparations Segment by Type
Single Drug
Combination Preparation
Niraparib Preparations Segment by Application
Ovarian Cancer
Prostate Cancer
Primary Peritoneal Cancer
Other
Niraparib Preparations Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Niraparib Preparations market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Niraparib Preparations and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Niraparib Preparations.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Niraparib Preparations market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Niraparib Preparations manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Niraparib Preparations in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Niraparib Preparations in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Single Drug
- Combination Preparation
Applications
- Ovarian Cancer
- Prostate Cancer
- Primary Peritoneal Cancer
- Other
Companies covered
- Zai Lab
- Takeda Pharmaceutical
- Janssen Biotech
- GSK
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Niraparib Preparations Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Niraparib Preparations Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Niraparib Preparations Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Niraparib Preparations Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Niraparib Preparations Market Dynamics
- 2.1 Niraparib Preparations Industry Trends
- 2.2 Niraparib Preparations Industry Drivers
- 2.3 Niraparib Preparations Industry Opportunities and Challenges
- 2.4 Niraparib Preparations Industry Restraints
3 Niraparib Preparations Market by Manufacturers
- 3.1 Global Niraparib Preparations Revenue by Manufacturers (2021-2026)
- 3.2 Global Niraparib Preparations Sales by Manufacturers (2021-2026)
- 3.3 Global Niraparib Preparations Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Niraparib Preparations Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Niraparib Preparations Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Niraparib Preparations Manufacturers, Product Type & Application
- 3.7 Global Niraparib Preparations Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Niraparib Preparations Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Niraparib Preparations Players Market Share by Revenue in 2025
- 3.8.3 2025 Niraparib Preparations Tier 1, Tier 2, and Tier 3
4 Niraparib Preparations Market by Type
- 4.1 Niraparib Preparations Type Introduction
- 4.1.1 Single Drug
- 4.1.2 Combination Preparation
- 4.2 Global Niraparib Preparations Sales by Type
- 4.2.1 Global Niraparib Preparations Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Niraparib Preparations Sales by Type (2021-2032)
- 4.2.3 Global Niraparib Preparations Sales Market Share by Type (2021-2032)
- 4.3 Global Niraparib Preparations Revenue by Type
- 4.3.1 Global Niraparib Preparations Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Niraparib Preparations Revenue by Type (2021-2032)
- 4.3.3 Global Niraparib Preparations Revenue Market Share by Type (2021-2032)
5 Niraparib Preparations Market by Application
- 5.1 Niraparib Preparations Application Introduction
- 5.1.1 Ovarian Cancer
- 5.1.2 Prostate Cancer
- 5.1.3 Primary Peritoneal Cancer
- 5.1.4 Other
- 5.2 Global Niraparib Preparations Sales by Application
- 5.2.1 Global Niraparib Preparations Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Niraparib Preparations Sales by Application (2021-2032)
- 5.2.3 Global Niraparib Preparations Sales Market Share by Application (2021-2032)
- 5.3 Global Niraparib Preparations Revenue by Application
- 5.3.1 Global Niraparib Preparations Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Niraparib Preparations Revenue by Application (2021-2032)
- 5.3.3 Global Niraparib Preparations Revenue Market Share by Application (2021-2032)
6 Global Niraparib Preparations Sales by Region
- 6.1 Global Niraparib Preparations Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Niraparib Preparations Sales by Region (2021-2032)
- 6.2.1 Global Niraparib Preparations Sales by Region (2021-2026)
- 6.2.2 Global Niraparib Preparations Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Niraparib Preparations Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Niraparib Preparations Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Niraparib Preparations Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Niraparib Preparations Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Niraparib Preparations Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Niraparib Preparations Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Niraparib Preparations Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Niraparib Preparations Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Niraparib Preparations Revenue by Region
- 7.1 Global Niraparib Preparations Revenue by Region
- 7.1.1 Global Niraparib Preparations Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Niraparib Preparations Revenue by Region (2021-2026)
- 7.1.3 Global Niraparib Preparations Revenue by Region (2027-2032)
- 7.1.4 Global Niraparib Preparations Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Niraparib Preparations Revenue (2021-2032)
- 7.2.2 North America Niraparib Preparations Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Niraparib Preparations Revenue (2021-2032)
- 7.3.2 Europe Niraparib Preparations Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Niraparib Preparations Revenue (2021-2032)
- 7.4.2 Asia-Pacific Niraparib Preparations Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Niraparib Preparations Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Niraparib Preparations Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Zai Lab
- 8.1.1 Zai Lab Company Information
- 8.1.2 Zai Lab Business Overview
- 8.1.3 Zai Lab Niraparib Preparations Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Zai Lab Niraparib Preparations Product Portfolio
- 8.1.5 Zai Lab Recent Developments
- 8.2 Takeda Pharmaceutical
- 8.2.1 Takeda Pharmaceutical Company Information
- 8.2.2 Takeda Pharmaceutical Business Overview
- 8.2.3 Takeda Pharmaceutical Niraparib Preparations Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Takeda Pharmaceutical Niraparib Preparations Product Portfolio
- 8.2.5 Takeda Pharmaceutical Recent Developments
- 8.3 Janssen Biotech
- 8.3.1 Janssen Biotech Company Information
- 8.3.2 Janssen Biotech Business Overview
- 8.3.3 Janssen Biotech Niraparib Preparations Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Janssen Biotech Niraparib Preparations Product Portfolio
- 8.3.5 Janssen Biotech Recent Developments
- 8.4 GSK
- 8.4.1 GSK Company Information
- 8.4.2 GSK Business Overview
- 8.4.3 GSK Niraparib Preparations Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 GSK Niraparib Preparations Product Portfolio
- 8.4.5 GSK Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Niraparib Preparations Value Chain Analysis
- 9.1.1 Niraparib Preparations Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Niraparib Preparations Production Mode & Process
- 9.2 Niraparib Preparations Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Niraparib Preparations Distributors
- 9.2.3 Niraparib Preparations Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst